Singapore markets closed
Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,691.29 +404.30 (+0.60%) CMC Crypto 200
1,424.45 -4.12 (-0.29%)
Kiora Pharmaceuticals, Inc. (KPRX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 12.94M |
| Enterprise value | -18.24M |
| Trailing P/E | N/A |
| Forward P/E | 2.53 |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 0.40 |
| Price/book (mrq) | 0.37 |
| Enterprise value/revenue | N/A |
| Enterprise value/EBITDA | N/A |
Trading information
Stock price history
| Beta (5Y monthly) | -0.19 |
| 52-week change 3 | -41.59% |
| S&P500 52-week change 3 | 23.49% |
| 52-week high 3 | 0.9980 |
| 52-week low 3 | 0.4510 |
| 50-day moving average 3 | 0.5456 |
| 200-day moving average 3 | 0.5741 |
Share statistics
| Avg vol (3-month) 3 | 193.01k |
| Avg vol (10-day) 3 | 120.15k |
| Shares outstanding 5 | 26.26M |
| Implied shares outstanding 6 | 26.26M |
| Float 8 | 13.18M |
| % held by insiders 1 | 0.86% |
| % held by institutions 1 | 50.14% |
| Shares short (15 May 2024) 4 | 66.53k |
| Short ratio (15 May 2024) 4 | 0.37 |
| Short % of float (15 May 2024) 4 | 0.26% |
| Short % of shares outstanding (15 May 2024) 4 | 0.25% |
| Shares short (prior month 15 Apr 2024) 4 | 73.44k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 30 Aug 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:40 |
| Last split date 3 | 27 Sept 2022 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 17.55% |
| Operating margin (ttm) | 82.56% |
Management effectiveness
| Return on assets (ttm) | 13.20% |
| Return on equity (ttm) | 12.46% |
Income statement
| Revenue (ttm) | 16M |
| Revenue per share (ttm) | 1.47 |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | 6.28M |
| Net income avi to common (ttm) | 2.28M |
| Diluted EPS (ttm) | -1.3100 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 31.28M |
| Total cash per share (mrq) | 1.19 |
| Total debt (mrq) | 94.3k |
| Total debt/equity (mrq) | 0.27% |
| Current ratio (mrq) | 21.02 |
| Book value per share (mrq) | 1.33 |
Cash flow statement
| Operating cash flow (ttm) | 7.14M |
| Levered free cash flow (ttm) | 4.13M |
© 2024 Yahoo. All rights reserved.